RXi Pharmaceuticals Corporation Company Profile (NASDAQ:RXII)

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation logoRXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RXII
  • CUSIP:
Key Metrics:
  • Previous Close: $0.70
  • 50 Day Moving Average: $0.698
  • 200 Day Moving Average: $1.396
  • 52-Week Range: $0.60 - $3.27
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.55
  • P/E Growth: 0.000
  • Market Cap: $4.59M
  • Outstanding Shares: 6,599,000
  • Beta: 1.24
Profitability:
  • Return on Equity: -155.62%
  • Return on Assets: -120.64%
Debt:
  • Current Ratio: 2.55%
  • Quick Ratio: 2.55%
Additional Links:
Companies Related to RXi Pharmaceuticals Corporation:

Analyst Ratings

Consensus Ratings for RXi Pharmaceuticals Corporation (NASDAQ:RXII) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.61 (274.82% upside)

Analysts' Ratings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Show:
DateFirmActionRatingPrice TargetDetails
11/21/2016S&P Equity ResearchLower Price Target$2.35 -> $1.71View Rating Details
6/7/2016HC WainwrightInitiated CoverageBuy$3.50View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2017        
11/10/2016Q316($0.34)($0.34)ViewN/AView Earnings Details
8/11/2016Q216($0.36)($0.34)ViewListenView Earnings Details
5/13/2016Q116($0.45)($0.34)$34.00 million$10.00 millionViewListenView Earnings Details
3/30/2016Q415($0.05)($0.04)ViewListenView Earnings Details
11/12/2015Q315($0.04)($0.04)ViewListenView Earnings Details
8/12/2015Q215($0.09)($0.05)ViewListenView Earnings Details
5/13/2015Q115($0.10)($0.13)ViewListenView Earnings Details
3/30/2015Q414($0.14)($0.13)ViewN/AView Earnings Details
11/13/2014Q314($0.22)($0.17)ViewN/AView Earnings Details
8/14/2014Q214($0.25)($0.23)ViewN/AView Earnings Details
5/14/2014Q114($0.31)($0.32)ViewN/AView Earnings Details
3/28/2014($0.31)$0.84ViewN/AView Earnings Details
11/14/2012Q312($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Current Year EPS Consensus Estimate: $-1.260 EPS
Next Year EPS Consensus Estimate: $-1.260 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.05)($0.05)($0.05)
Q3 20161($0.32)($0.32)($0.32)
Q4 20161($0.23)($0.23)($0.23)
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.17)($0.17)($0.17)
Q4 20171($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Insider Ownership Percentage: 4.16%
Institutional Ownership Percentage: 7.42%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/17/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
2/8/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
1/25/2017Geert CauwenberghCEOBuy10,000$0.70$7,000.00View SEC Filing  
1/19/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
4/2/2015Geert CauwenberghCEOBuy5,000$0.72$3,600.00View SEC Filing  
2/17/2015Geert CauwenberghCEOBuy4,000$1.17$4,680.00View SEC Filing  
2/10/2015Geert CauwenberghCEOBuy2,000$1.24$2,480.00View SEC Filing  
1/22/2015Robert J BittermanDirectorBuy5,000$1.20$6,000.00View SEC Filing  
1/20/2015Geert CauwenberghCEOBuy10,000$1.03$10,300.00View SEC Filing  
12/30/2014Geert CauwenberghCEOBuy2,500$1.59$3,975.00View SEC Filing  
10/13/2014Geert CauwenberghCEOBuy3,000$1.68$5,040.00View SEC Filing  
9/19/2014Geert CauwenberghCEOBuy4,500$2.20$9,900.00View SEC Filing  
9/16/2014Geert CauwenberghCEOBuy5,000$2.08$10,400.00View SEC Filing  
9/15/2014Geert CauwenberghCEOBuy10,000$2.18$21,800.00View SEC Filing  
7/15/2014Geert CauwenberghCEOBuy1,000$2.50$2,500.00View SEC Filing  
7/9/2014Geert CauwenberghCEOBuy1,400$2.57$3,598.00View SEC Filing  
7/2/2014Geert CauwenberghCEOBuy2,000$2.86$5,720.00View SEC Filing  
6/19/2014Geert CauwenberghCEOBuy2,000$2.98$5,960.00View SEC Filing  
6/9/2014Geert CauwenberghCEOBuy1,000$3.05$3,050.00View SEC Filing  
6/4/2014Geert CauwenberghCEOBuy2,000$2.94$5,880.00View SEC Filing  
10/31/2013Geert CauwenberghCEOBuy1,000$3.17$3,170.00View SEC Filing  
10/23/2013Geert CauwenberghCEOBuy1,000$3.34$3,340.00View SEC Filing  
10/9/2013Geert CauwenberghCEOBuy1,000$3.15$3,150.00View SEC Filing  
8/29/2013Curtis LockshinDirectorBuy1,000$3.70$3,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
DateHeadline
finance.yahoo.com logoThe Life Sciences Report Examines How the RXi-MirImmune Merger Is Aiming to Unlock Value Through Groundbreaking Technology (NASDAQ:RXII)
finance.yahoo.com - February 23 at 7:48 PM
News IconInvestor Watch on Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Benton Bulletin (NASDAQ:RXII)
bentonbulletin.com - February 22 at 7:49 PM
News IconCritical Chart Information For RXi Pharmaceuticals Corporation (RXII) - NY Stock News (NASDAQ:RXII)
nystocknews.com - February 22 at 7:49 PM
marketexclusive.com logoInsider Trading Activity RXi Pharmaceuticals Corporation (NASDAQ:RXII) – CEO Bought 10,000 shares of Stock (NASDAQ:RXII)
marketexclusive.com - February 21 at 5:12 PM
finance.yahoo.com logoRXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, to Scientific Advisory Board (NASDAQ:RXII)
finance.yahoo.com - February 15 at 1:38 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences (NASDAQ:RXII)
finance.yahoo.com - February 8 at 11:49 PM
prnewswire.com logoRXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, to Scientific Advisory Board - PR Newswire (press release) (NASDAQ:RXII)
www.prnewswire.com - February 7 at 8:13 AM
finance.yahoo.com logoRXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, to Scientific Advisory Board (NASDAQ:RXII)
finance.yahoo.com - February 7 at 8:13 AM
News IconNews Impact Score Of RXI Pharmaceuticals Corporation (NASDAQ:RXII) At 50 - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - February 4 at 4:46 AM
marketexclusive.com logoRXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII) Files An 8-K Notice of Delisting or Failure to Satisfy a ... - Market Exclusive (NASDAQ:RXII)
marketexclusive.com - February 4 at 4:46 AM
News IconRXI Pharmaceuticals Corporation (NASDAQ:RXII) Quarterly EPS Projection At $-0.23 - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - January 29 at 8:17 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Wall Street Beacon (NASDAQ:RXII)
wsbeacon.com - January 22 at 8:15 AM
News IconRXi Pharmaceuticals Corporation (NASDAQ:RXII):Brokerage Firm Rating Analysis - Highland Mirror (NASDAQ:RXII)
www.highlandmirror.com - January 20 at 11:23 PM
News IconGrowth Story Unfolding for RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Prospect Journal (NASDAQ:RXII)
prospectjournal.com - January 17 at 12:11 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Wall Street Beacon (NASDAQ:RXII)
wsbeacon.com - January 16 at 1:37 PM
News IconStocks Carrying Extraordinary Return Ratio: RXi Pharmaceuticals (NASDAQ:RXII), Sarepta Therapeutics (NASDAQ ... - Street Wise Report (press release) (blog) (NASDAQ:RXII)
streetwisereport.com - January 16 at 1:37 PM
News IconEPS Of RXI Pharmaceuticals Corporation (NASDAQ:RXII) At $-0.23 - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - January 15 at 8:29 AM
smarteranalyst.com logoStock Update (NASDAQ:RXII): Here's Why RXi Pharmaceuticals Corp Shares Rose 25% - Smarter Analyst (NASDAQ:RXII)
www.smarteranalyst.com - January 15 at 8:29 AM
smarteranalyst.com logoStock Update (NASDAQ:RXII): Here’s Why RXi Pharmaceuticals Corp Shares Rose 25% (NASDAQ:RXII)
www.smarteranalyst.com - January 14 at 6:02 AM
News IconIs This Equity Ready for a Breakout: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Prospect Journal (NASDAQ:RXII)
prospectjournal.com - January 13 at 2:01 AM
News IconNews Impact Score Of RXI Pharmaceuticals Corporation (NASDAQ:RXII) Set At 0 - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - January 13 at 2:01 AM
seekingalpha.com logoRXi Pharmaceuticals Acquires MirImmune For Cancer Immunotherapy Prospects - Seeking Alpha (NASDAQ:RXII)
seekingalpha.com - January 13 at 2:01 AM
News IconRXi Pharmaceuticals Corp RXII Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RXII)
www.bioportfolio.com - January 12 at 9:00 PM
News IconBoom or Bust? Is there any value in RXi Pharmaceuticals ... - Prospect Journal (NASDAQ:RXII)
prospectjournal.com - January 11 at 3:21 AM
seekingalpha.com logoRXi Pharmaceuticals (RXII) presents at 9th Annual Biotech Showcase Conference (NASDAQ:RXII)
seekingalpha.com - January 10 at 10:21 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ (NASDAQ:RXII)
biz.yahoo.com - January 10 at 10:21 PM
finance.yahoo.com logoRXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New Chief Business Officer (NASDAQ:RXII)
finance.yahoo.com - January 9 at 9:21 AM
News IconRXI Pharmaceuticals Corporation (NASDAQ:RXII) News Impact Score At 0 - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - January 8 at 12:22 AM
News IconInvestor Focus on Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Wall Street Beacon (NASDAQ:RXII)
wsbeacon.com - January 8 at 12:22 AM
News IconMF Rank in Focus for RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Wall Street Beacon (NASDAQ:RXII)
wsbeacon.com - January 3 at 9:50 AM
investornewswire.com logoRXI Pharmaceuticals Corporation (NASDAQ:RXII) Strong Buy Recommendations At 2 - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - January 2 at 8:00 AM
News IconRXI Pharmaceuticals Corporation (NASDAQ:RXII) EPS At $-0.23 - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - January 1 at 12:28 AM
News IconIntrexon Corp. (XON) Receives New Coverage from Analysts at Northland Securities (NASDAQ:RXII)
itapunta.com - December 31 at 1:01 AM
News IconOpko Health Inc (NASDAQ:OPK) Broker Price Targets For The Coming Week (NASDAQ:RXII)
flapship.com - December 30 at 7:59 PM
News IconRXI Pharmaceuticals Corporation (NASDAQ:RXII) News Impact Score At 100 - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - December 30 at 8:27 AM
News IconShares in Review: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Wall Street Beacon (NASDAQ:RXII)
wsbeacon.com - December 30 at 8:27 AM
News IconEPS Of RXI Pharmaceuticals Corporation (NASDAQ:RXII) Set At ... - Stock Observer (NASDAQ:RXII)
www.thestockobserver.com - December 26 at 9:17 AM
prnewswire.com logoRXi Pharmaceuticals to Present at the 9th Annual Biotech Showcase™ - PR Newswire (press release) (NASDAQ:RXII)
www.prnewswire.com - December 26 at 9:17 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the 9th Annual Biotech Showcase™ (NASDAQ:RXII)
finance.yahoo.com - December 26 at 9:17 AM
marketexclusive.com logoRXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (NASDAQ:RXII)
marketexclusive.com - December 24 at 12:50 AM
prnewswire.com logoRXi Pharmaceuticals Announces Closing of $11.5 Million ... - PR Newswire (press release) (NASDAQ:RXII)
www.prnewswire.com - December 23 at 7:49 PM
News IconPopping up on Watch-lists are Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Prospect Journal (NASDAQ:RXII)
prospectjournal.com - December 23 at 7:49 PM
News IconRXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-allotment Optio... (NASDAQ:RXII)
ih.advfn.com - December 21 at 10:10 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submiss (NASDAQ:RXII)
biz.yahoo.com - December 21 at 10:10 PM
News IconBargain Hunters Should Take a Look at RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Prospect Journal (NASDAQ:RXII)
prospectjournal.com - December 21 at 12:39 AM
News IconInside the Numbers for RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Business Daily Leader (NASDAQ:RXII)
businessdailyleader.com - December 20 at 2:28 PM
News IconROIC Watch for RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Wall Street Beacon (NASDAQ:RXII)
wsbeacon.com - December 20 at 2:28 PM
News IconRXi Pharmaceuticals Corp (NASDAQ:RXII) Should Recover On Catalysts Near Term - Insider Financial (NASDAQ:RXII)
www.insiderfinancial.com - December 20 at 2:28 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat (NASDAQ:RXII)
biz.yahoo.com - December 20 at 2:28 PM
News IconInvestor Hub: Looking at Shares of RXi Pharmaceuticals Corporation - Wall Street Beacon (NASDAQ:RXII)
wsbeacon.com - December 18 at 1:30 AM

Social

What is RXi Pharmaceuticals Corporation's stock symbol?

RXi Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "RXII."

Where is RXi Pharmaceuticals Corporation's stock going? Where will RXi Pharmaceuticals Corporation's stock price be in 2017?

1 brokers have issued 12 month price targets for RXi Pharmaceuticals Corporation's stock. Their predictions range from $1.71 to $3.50. On average, they anticipate RXi Pharmaceuticals Corporation's stock price to reach $2.61 in the next twelve months.

When will RXi Pharmaceuticals Corporation announce their earnings?

RXi Pharmaceuticals Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.

Who owns RXi Pharmaceuticals Corporation stock?

RXi Pharmaceuticals Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.49%).

Who bought RXi Pharmaceuticals Corporation stock? Who is buying RXi Pharmaceuticals Corporation stock?

RXi Pharmaceuticals Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy RXi Pharmaceuticals Corporation stock?

Shares of RXi Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of RXi Pharmaceuticals Corporation stock cost?

One share of RXi Pharmaceuticals Corporation stock can currently be purchased for approximately $0.70.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Earnings History Chart

Earnings by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Dividend History Chart

Dividend Payments by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Last Updated on 2/25/2017 by MarketBeat.com Staff